A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

ESMO Open · Published 2026-07-09 · DOI 10.1016/j.esmoop.2026.108303

Free full text

Authors (14)

S.J. Shin, J.L. Lee, T. Powles, J. Martin-Liberal, R. Morales-Barrera, Alexandra Drakaki, T. Friedlander, F. Joly, S.A. Shah, J. Vuky, I. Ianculescu, F. Michielin, X. Gan, A. Bamias

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Shin, S., Lee, J., Powles, T., et al. (2026). A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma). ESMO Open. https://doi.org/10.1016/j.esmoop.2026.108303

Related articles